MaxCyte to Participate in Upcoming Investor Conferences

Rhea-AI Summary

MaxCyte, a commercial cell-engineering company, announced its participation in several investor conferences. The events include the Consilium Strategic Communications 9th Annual Healthcare Conference on November 15, 2021, Stifel 2021 Virtual Healthcare Conference on November 16, and Stephens Annual Investment Conference on November 29. Each session will feature discussions led by company management. Live and archived webcasts will be available on MaxCyte's investor relations website.

GAITHERSBURG, Md., Nov. 12, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced Company management will participate in the following investor conferences:

• Consilium Strategic Communications 9th Annual Healthcare Conference 2021
  Panel discussion on Monday, November 15^th at 8:50 a.m. Eastern Time

• Stifel 2021 Virtual Healthcare Conference
  Fireside chat on Tuesday, November 16^th at 8:00 a.m. Eastern Time

• Stephens Annual Investment Conference
  Fireside chat on Monday, November 29^th at 12:00 p.m. Eastern Time

Live and archived webcasts of the events will be available on the “Events” section of the MaxCyte investor relations website at https://investors.maxcyte.com/.

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: three instruments, the ATx™, STx™ and GTx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

MaxCyte Contacts:

US IR Adviser
Gilmartin Group	+1 415-937-5400
David Deuchler, CFA	ir@maxcyte.com
Nominated Adviser and Joint Corporate Broker
Panmure Gordon	+44 (0)20 7886 2500
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
UK IR Adviser	+44 (0)203 709 5700
Consilium Strategic Communications	maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh

FAQ

What investor conferences will MaxCyte participate in November 2021?

MaxCyte will participate in the Consilium Strategic Communications 9th Annual Healthcare Conference on November 15, Stifel 2021 Virtual Healthcare Conference on November 16, and the Stephens Annual Investment Conference on November 29, 2021.

What time is the Consilium Healthcare Conference panel discussion for MaxCyte?

The panel discussion at the Consilium Strategic Communications 9th Annual Healthcare Conference will take place on November 15, 2021, at 8:50 a.m. Eastern Time.

Where can I watch the MaxCyte conference webcasts?

Live and archived webcasts of the conferences will be available on MaxCyte's investor relations website under the Events section.

What is the focus of MaxCyte's technology?

MaxCyte focuses on providing platform technologies for cell-based research, including development and commercialization of next-generation cell therapies.

What is the ticker symbol for MaxCyte?

MaxCyte's ticker symbol is MXCT, listed on NASDAQ.